Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75223
UPID:
GGCT_HUMAN
Alternative names:
Cytochrome c-releasing factor 21
Alternative UPACC:
O75223; B2RDN0; B8ZZN4; B8ZZR8; Q9BS37
Background:
Gamma-glutamylcyclotransferase, also known as Cytochrome c-releasing factor 21, plays a pivotal role in glutathione homeostasis by catalyzing the formation of 5-oxoproline from gamma-glutamyl dipeptides. Its ability to induce the release of cytochrome c from mitochondria underscores its importance in apoptosis regulation.
Therapeutic significance:
Understanding the role of Gamma-glutamylcyclotransferase could open doors to potential therapeutic strategies. Its involvement in glutathione homeostasis and apoptosis makes it a compelling target for drug discovery efforts aimed at treating diseases where these processes are dysregulated.